Literature DB >> 11240033

Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling.

T Misu1, H Onodera, K Fujihara, K Matsushima, O Yoshie, N Okita, S Takase, Y Itoyama.   

Abstract

The expression of chemokine receptors on lymphocytes in the blood and CSF of multiple sclerosis (MS) patients was analyzed at relapse and remission. Both CD4+ and CD8+ cells in CSF at relapse were enriched for Th1-type receptors CXCR3 and CCR5 expression, and were reduced for Th2-type receptors CCR3 and CCR4 expression compared with those of the blood. CCR1 and CCR2 expressions on T cells were increased in CSF and blood, respectively. At remission, CCR5 expression, but not CXCR3 expression, was reduced in CSF CD4+ cells. A biased Th1/Th2 balance may play a critical role in active inflammation and CCR5 on CSF CD4+ cells is a good marker of the disease activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11240033     DOI: 10.1016/s0165-5728(00)00456-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  26 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking.

Authors:  P Kivisäkk; C Trebst; Z Liu; B H Tucky; T L Sørensen; R A Rudick; M Mack; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

3.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 4.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

5.  Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis.

Authors:  Makoto Matsui; Shin-ichi Araya; Hui-Yun Wang; Kouji Matsushima; Takahiko Saida
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

6.  Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica.

Authors:  Koichi Narikawa; Tatsuro Misu; Kazuo Fujihara; Ichiro Nakashima; Shigeru Sato; Yasuto Itoyama
Journal:  J Neurol       Date:  2005-07-18       Impact factor: 4.849

7.  Gatekeeper role of brain antigen-presenting CD11c+ cells in neuroinflammation.

Authors:  Magdalena Paterka; Volker Siffrin; Jan O Voss; Johannes Werr; Nicola Hoppmann; René Gollan; Patrick Belikan; Julia Bruttger; Jérôme Birkenstock; Steffen Jung; Enric Esplugues; Nir Yogev; Richard A Flavell; Tobias Bopp; Frauke Zipp
Journal:  EMBO J       Date:  2015-11-26       Impact factor: 11.598

8.  Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis.

Authors:  Hideto Nakajima; Masakazu Sugino; Fumiharu Kimura; Toshiaki Hanafusa; Toshiyuki Ikemoto; Akira Shimizu
Journal:  Biomark Insights       Date:  2007-12-18

9.  Linkage and haplotype analysis for chemokine receptors clustered on chromosome 3p21.3 and transmitted in family pedigrees with asthma and atopy.

Authors:  Saleh A Al-Abdulhadi; Mohammed W O Al-Rabia
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

Review 10.  T helper cell polarization in healthy people: implications for cardiovascular disease.

Authors:  Nels C Olson; Reem Sallam; Margaret F Doyle; Russell P Tracy; Sally A Huber
Journal:  J Cardiovasc Transl Res       Date:  2013-08-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.